National kidney allograft sharing: A decision analysis

Transplantation

Volumn 64, Issue 1, 1997, Pages 80-88

  Feldman, Harold I ^a   Roth, David A ^b   Fazio, Ignazio ^c   Grossman, Robert A ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b TEMPLE UNIVERSITY HOSPITAL   (United States)

^c ST JOSEPH S REGIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN;

ALLELE; ALLOGRAFT; ARTICLE; CADAVER KIDNEY; GOVERNMENT; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH PROGRAM; HISTOCOMPATIBILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; UNITED STATES;

ALLELES; CADAVER; DECISION SUPPORT TECHNIQUES; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; UNITED STATES;

EID: 0030789607     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199707150-00015     Document Type: Article

References (37)

1. United States Renal Data System. USRDS 1994 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, July 1994.
2. Hunsicker LG, Held PJ. The role of HLA matching for cadaveric renal transplants in the cyclosporine era. Semin Nephrol 1992; 19 : 293.
3. Cicciarelli J, Cho Y. HLA matching: univariate and multivariate analyses of UNOS registry data. In: Terasaki P, ed. Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1991: 325.
4. Opelz G, for the Collaborative Transplant Study. Effect of HLA matching in 10,000 cyclosporine-treated cadaver kidney transplants. Transplant Proc 1987; 19: 641.
5. Alexander JW, Vaughn WK, Pfaff WW. Local use of kidneys with poor HLA matches is as good as shared use with good matches in the cyclosporine era: an analysis at one and two years. Transplant Proc 1987; 19: 672.
6. Carpenter CB, Goguen JF, Bradley JW, Turka, LA, Cho SI, Milford EL. HLA-B, DR matching and cadaver renal allograft survival in New England. Transplant Proc 1989; 21: 663.
7. Fesenstein H, Doyle P, Holmes J. Long-term follow-up in London transplant group recipients of cadaveric renal allografts: the influence of HLA matching on transplant outcome. N Engl J Med 1986; 314: 7.
8. Persijn GG, D'Amaro J, de Lange P, Schreuder GM, van Rood JJ. Modulation of the HLA-A, -B, and -DR matching effect by cyclosporine therapy. Transplant Proc 1989; 21: 656.
9. Sanfilippo F, Vaughn WK, Spees EK, Light JA, LeFor WM. Benefits of HLA-A and HLA-B matching on graft and patient outcome after cadaveric-donor renal transplantation. N Engl J Med 1984; 311: 358.
10. Gjertson DW, Terasaki PI, Takemoto S, Mickey MR. National allocation of cadaveric kidneys by HLA matching. N Engl J Med 1991; 324: 1032.
11. Takiff H, Iwaki Y, Cecka M, Terasaki PI. The benefit and underutilization of sharing kidneys for better histocompatibility. Transplantation 1989; 47: 102.
12. Sanfilippo F, Vaughn WK, Alexander JW, LeFor WM, Lucas BA, Pfaff WW. Organ sharing for good HLA-A, B, and DR matching improves cadaveric renal allograft survival in SEOPF: retrospective and prospective studies considering delayed graft function, race, center effects, cyclosporine, and other factors. Clin Transpl 1988: 211.
13. Terasaki PI. Nationwide organ sharing using HLA typing. Kidney Int 1991; 39: 557.
14. Takemoto S, Terasaki PI, Cecka M, Cho YW, Gjertson DW, for the UNOS Scientific Renal Transplant Registry. Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors. N Engl J Med 1992; 327: 834.
15. Held PJ, Kahan BD, Hunsicker LG, et al. The impact of HLA mismatches on the survival of first cadaveric kidney transplants. N Engl J Med 1994; 331: 765.
16. 1993 Annual Report of the U.S. Scientific Registry for Transplant Recipients and the Organ Procurement and Transplantation Network - Transplant Data: 1988-1991. Richmond, VA: UNOS, and Bethesda, MD: Division of Organ Transplantation, Bureau of Health Resources Development, Health Resources and Services Administration, US Department of Health and Human Services, 1993.
17. Sanfilippo F, Vaughn WK, Spees EK, Lucas BA. The detrimental effects of delayed graft function in cadaver donor renal transplantation. Transplantation 1984; 38: 643.
18. The Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation: analysis at three years. N Engl J Med 1986; 314: 1219.
19. Rosenthal JT, Danovitch GM, Wilkinson A, Ettenger RB. The high cost of delayed graft function in cadaveric renal transplantation. Transplantation 1991; 51: 1115.
20. Isa WA, Robles JE, Rosell D, et al. Cadaveric renal transplantation: multifactorial analysis of possible causes affecting graft outcome in recipients treated with and without cyclosponne. Transplantation 1992; 24: 115.
21. Howard RJ, Pfaff WW, Brunson ME, et al. Increased incidence of rejection in patients with delayed graft function. Transplantation 1994; 8: 527.
22. Cecka JM, Cho YW, Terasaki PI. Analyses of the UNOS scientific renal transplant registry at three years: early events affecting transplant success. Transplantation 1992; 53: 59.
23. Feldman HI, Gayner R, Silibovsky R, Kushner S, Donn A, Berlin JA. Effect of delayed graft function (DGF) on long-term renal allograft survival. Clin Res 1993; 41: 327A.
24. United States Renal Data System. USRDS 1990 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, July 1990.
25. Halloran PF, Aprile MA, Farewell V, et al. Early function as the principal correlate of graft survival: a multivariate analysis of 200 cadaveric renal transplants treated with a protocol incorporating antilvmphocyte globulin and cyclosporine. Transplantation 1988; 46: 223.
26. Canafax DM, Torres A, Fryd DS, et al. The effects of delayed function on recipients of cadaver renal allografts: a study of 158 patients randomized to cyclosporine or ALG-azathioprine. Transplantation 1986; 41: 177.
27. Kahan BD, Mickey R, Flechner SM, et al. Multivariate analysis of risk factors impacting on immediate and eventual cadaver allograft survival in cyclosporine-treated recipients. Transplantation 1987; 43: 65.
28. Jordan ML, Aprile MA, Cardella CJ. The role of cold ischemia in a provincial organ-sharing program in the cyclosporine era. Transplantation 1990; 49: 367.
29. Cacciarelli T, Sumrani N, Delaney V, Hong JH, DiBenedetto A, Sommer BG. The influence of delayed renal allograft function on long-term outcome in the cyclosporine era. Clin Nephrol 1993; 39: 335.
30. Corman J, Moukarzel M, Guttmann R, et al. Quebec metrotransplantation multicenter study on delayed graft function in kidney transplantation. Transplant Proc 1988; 20(Suppl 1): 428.
31. Peters TG, Shaver TR, Ames JE, Santagio-Delpin EA, Jones KW, Blanton JW. Cold ischemia and outcome in 17,937 cadaveric kidney transplants. Transplantation. 1995; 59: 191.
32. Zhou Y-C, Cecka JM. Preservation. Clin Transpl 1992: 383.
33. Asch DA, Hershey JC. Why some health policies don't make sense at the bedside. Ann Intern Med 1995; 122: 846.
34. Feduska NJ, Melzer J, Amend WJC, Vincenti F, Tomlanovich S, Salvatierra O Jr. Analysis of some factors that might affect the outcome for cadaveric kidney transplants in cyclosporine-treated patients. Transplant Proc 1986; 18: 519.
35. Neumayer H-H, Link J, Muhlber J, Wagner K. Factors influencing primary kidney graft function. Transplant Proc 1986; 18: 506.
36. Sommer BG, Henry M, Ferguson RM. sequential antilymphoblast globulin and cyclosporine for renal transplantation. Transplantation 1987; 43: 85.
37. Gaston RS, Ayres I, Dooley LG, Diethelm AG. Racial equity in renal transplantation. JAMA 1993; 270: 1352.